Over the past decade, the carcinogenic effects of HMGB3 have been reported in a variety of tumors, including colorectal cancer (CRC) (Zhang et al., 2017), breast cancer (BC) (Gu et al., 2019), cervical cancer (Li Z. et al., 2020; Zhuang et al., 2020), and non-small cell lung cancer (NSCLC) (Li Y. et al., 2020). Here, HMGB3 is linked to breast cancer.